NMTC1
MCID: THY109
MIFTS: 59

Thyroid Cancer, Nonmedullary, 1 (NMTC1)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Thyroid Cancer, Nonmedullary, 1

MalaCards integrated aliases for Thyroid Cancer, Nonmedullary, 1:

Name: Thyroid Cancer, Nonmedullary, 1 58
Papillary Thyroid Carcinoma 12 54 30 6 15 17 74
Familial Nonmedullary Thyroid Cancer, Papillary 58 54 76
Nonmedullary Thyroid Carcinoma, Papillary 58 54 76
Nonmedullary Thyroid Carcinoma 1 13 6
Non-Medullary Thyroid Carcinoma 76 74
Papillary Carcinoma of Thyroid 58 76
Thyroid Carcinoma, Papillary 77 13
Nmtc1 58 76
Pact 58 76
Papillary Carcinoma of Thyroid; Pact; Ptc; Tpc 58
Familial Nonmedullary Thyroid Gland Carcinoma 74
Papillary Carcinoma of the Thyroid Gland 12
Familial Non-Medullary Thyroid Cancer 76
Cancer, Thyroid, Nonmedullary, Type 1 41
Thyroid Carcinoma, Nonmedullary 1 74
Thyroid Cancer, Non-Medullary, 1 76
Nonmedullary Thyroid Carcinoma 76
Cancer, Thyroid, Nonmedullary 41
Thyroid Papillary Carcinoma 56
Papillary Thyroid Cancer 56
Fnmtc 76
Nmtc 76
Ptc 76
Tpc 76

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
thyroid cancer, nonmedullary, 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:3969
OMIM 58 188550
NCIt 51 C4035
SNOMED-CT 69 4797003
MedGen 43 C0238463
SNOMED-CT via HPO 70 255029007 263681008 3716002

Summaries for Thyroid Cancer, Nonmedullary, 1

OMIM : 58 Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular (188470), Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100; Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). PTC is characterized by distinctive nuclear alterations including pseudoinclusions, grooves, and chromatin clearing. PTCs smaller than 1 cm are referred to as papillary microcarcinomas. These tumors have been identified in up to 35% of individuals at autopsy, suggesting that they may be extremely common although rarely clinically relevant. PTC can also be multifocal but is typically slow-growing with a tendency to spread to lymph nodes and usually has an excellent prognosis (summary by Bonora et al., 2010). (188550)

MalaCards based summary : Thyroid Cancer, Nonmedullary, 1, also known as papillary thyroid carcinoma, is related to struma ovarii and differentiated thyroid carcinoma. An important gene associated with Thyroid Cancer, Nonmedullary, 1 is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are miRs in Muscle Cell Differentiation and LncRNA-mediated mechanisms of therapeutic resistance. The drugs Iodine and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and endothelial, and related phenotypes are goiter and papillary thyroid carcinoma

Disease Ontology : 12 A thyroid carcinoma that is characterized by the small mushroom shape of the tumor which has a stem attached to the epithelial layer.

NIH Rare Diseases : 54 Papillary thyroid carcinoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of certain cells (follicular cells) of the thyroid. Many people with papillary thyroid carcinoma have no signs or symptoms of the condition. When present, symptoms may include a small lump at the base of the neck, hoarseness, difficulty swallowing, trouble breathing, and pain in the neck or throat. Although people of all ages may be diagnosed with the condition, women between ages 30 and 50 are most commonly affected. The cause of papillary thyroid carcinoma is currently unknown. Risks for developing thyroid cancer include a history of high-dose external radiation treatments to the neck and radiation exposure during nuclear plant disasters. The best treatment options depend on many factors, but may include surgery, radiation therapy (including radioactive iodine therapy), chemotherapy and thyroid hormone therapy.

UniProtKB/Swiss-Prot : 76 Thyroid cancer, non-medullary, 1: A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

Wikipedia : 77 Papillary thyroid cancer or papillary thyroid carcinoma is the most common type of thyroid cancer,... more...

Related Diseases for Thyroid Cancer, Nonmedullary, 1

Diseases in the Thyroid Cancer, Nonmedullary, 2 family:

Thyroid Cancer, Nonmedullary, 1 Thyroid Cancer, Nonmedullary, 3
Thyroid Cancer, Nonmedullary, 4 Thyroid Cancer, Nonmedullary, 5

Diseases related to Thyroid Cancer, Nonmedullary, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 360)
# Related Disease Score Top Affiliating Genes
1 struma ovarii 31.5 BRAF NKX2-1
2 differentiated thyroid carcinoma 31.1 BRAF GAS8-AS1 NKX2-1
3 thyroid cancer 31.0 BRAF GAS5 HOTAIR MALAT1 NKX2-1 PTCSC3
4 lung cancer susceptibility 3 30.8 BRAF GAS5 HOTAIR LINC-ROR MALAT1 NKX2-1
5 dermatomyositis 30.8 MIR221 MIR222
6 melanoma 30.7 BANCR BRAF GAS5 HOTAIR LINC-ROR MALAT1
7 papillary thyroid microcarcinoma 30.7 BRAF NKX2-1
8 diffuse large b-cell lymphoma 30.6 HOTAIR HULC MIR221
9 pituitary adenoma 30.6 HOTAIR MALAT1
10 tongue squamous cell carcinoma 30.4 HOTTIP MALAT1 MIR222
11 prostate cancer 30.4 GAS5 HOTAIR HOTTIP HULC MALAT1 MIR146A
12 ovarian cancer 30.4 BRAF GAS5 HOTAIR LINC-ROR MALAT1 MIR146A
13 myeloma, multiple 30.4 BRAF GAS5 HOTAIR MALAT1
14 squamous cell carcinoma, head and neck 30.4 BRAF GAS5 HOTAIR MIR221
15 renal cell carcinoma, nonpapillary 30.4 GAS5 HOTAIR LINC-ROR MALAT1 NKX2-1
16 breast cancer 30.3 BRAF GAS5 HOTAIR HOTTIP LINC-ROR MALAT1
17 glioblastoma 30.3 BRAF GAS5 HOTAIR MALAT1 MIR221 MIR222
18 esophageal cancer 30.2 GAS5 HOTAIR HOTTIP HULC LINC-ROR MALAT1
19 bladder cancer 30.2 BANCR GAS5 HOTAIR HULC MALAT1 MIR221
20 pancreatic cancer 30.1 GAS5 HOTAIR HOTTIP HULC LINC-ROR MALAT1
21 glioma 30.1 BRAF CCND2-AS1 GAS5 HOTAIR HOTTIP HULC
22 hepatocellular carcinoma 30.0 BANCR GAS5 HOTAIR HOTTIP HULC LINC-ROR
23 gastric cancer 30.0 BANCR GAS5 HAGLROS HOTAIR HOTTIP HULC
24 colorectal cancer 30.0 BANCR BRAF GAS5 HOTAIR HOTTIP HULC
25 multicentric papillary thyroid carcinoma 12.5
26 thyroid cancer, nonmedullary, 3 11.6
27 thiourea tasting 11.5
28 thyroid carcinoma, papillary, with papillary renal neoplasia 11.3
29 thyroid carcinoma, nonmedullary, with or without cell oxyphilia 11.2
30 familial papillary or follicular thyroid carcinoma 11.1
31 thyroid cancer, nonmedullary, 2 11.1
32 thyroid cancer, nonmedullary, 4 11.1
33 thyroid cancer, nonmedullary, 5 11.1
34 papillary carcinoma 10.8
35 esophagus squamous cell carcinoma 10.5 BANCR HOTAIR
36 triple-receptor negative breast cancer 10.5 HOTAIR LINC-ROR MALAT1
37 ovarian epithelial cancer 10.5 HOTAIR HULC MALAT1
38 coronary heart disease 1 10.5 GAS5 HOTTIP MIR221 MIR222
39 malignant glioma 10.5 GAS5 HOTAIR HOTTIP
40 oral squamous cell carcinoma 10.5 HOTAIR MALAT1 MIR146A MIR221
41 hyperparathyroidism 10.5
42 small cell cancer of the lung 10.4 HOTAIR HOTTIP MALAT1 NKX2-1
43 primary hyperparathyroidism 10.4
44 pancreatic ductal adenocarcinoma 10.4 HOTAIR HOTTIP MALAT1 MIR146A MIR221
45 bladder urothelial carcinoma 10.4 BRAF GAS5 HOTAIR MALAT1
46 familial adenomatous polyposis 10.4
47 gastrointestinal system cancer 10.4 BANCR HOTAIR MALAT1
48 leukemia, acute myeloid 10.4 HOTAIR MALAT1 MIR146A MIR221 MIR222
49 kidney cancer 10.4 GAS5 HOTAIR MALAT1
50 liver cirrhosis 10.4 GAS5 HOTAIR HULC MALAT1

Graphical network of the top 20 diseases related to Thyroid Cancer, Nonmedullary, 1:



Diseases related to Thyroid Cancer, Nonmedullary, 1

Symptoms & Phenotypes for Thyroid Cancer, Nonmedullary, 1

Human phenotypes related to Thyroid Cancer, Nonmedullary, 1:

33
# Description HPO Frequency HPO Source Accession
1 goiter 33 HP:0000853
2 papillary thyroid carcinoma 33 HP:0002895
3 non-medullary thyroid carcinoma 33 HP:0040198

Symptoms via clinical synopsis from OMIM:

58
Neoplasia:
nonmedullary thyroid carcinoma (papillary)
goiter, multinodular

Clinical features from OMIM:

188550

Drugs & Therapeutics for Thyroid Cancer, Nonmedullary, 1

Drugs for Thyroid Cancer, Nonmedullary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 7553-56-2 807
2 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
3 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
4 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
5 cadexomer iodine Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
6 Trace Elements Phase 2, Phase 3,Phase 3,Phase 1
7 Micronutrients Phase 2, Phase 3,Phase 3,Phase 1
8 Nutrients Phase 2, Phase 3,Phase 3,Phase 1
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
10 Hormone Antagonists Phase 3,Phase 2
11
Rosiglitazone Approved, Investigational Phase 2,Phase 1 122320-73-4 77999
12
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
13
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
14
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
15
Indinavir Approved Phase 2 150378-17-9 5362440
16
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
17
Parathyroid hormone Approved, Investigational Phase 2,Phase 1 9002-64-6
18
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
19
Azacitidine Approved, Investigational Phase 2,Phase 1 320-67-2 9444
20
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
21
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
22
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
23
Calcium Carbonate Approved, Investigational Phase 2 471-34-1
24
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
25
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
26
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
27
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
28
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
29
Gefitinib Approved, Investigational Phase 2,Not Applicable 184475-35-2 123631
30
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
31
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
32
Sodium Citrate Approved, Investigational Phase 2 68-04-2
33
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
34
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
35
Tamoxifen Approved Phase 2 10540-29-1 2733526
36
Dabrafenib Approved, Investigational Phase 2,Phase 1,Not Applicable 1195765-45-7 44462760 44516822
37
Salmon Calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
38
Lenvatinib Approved, Investigational Phase 2 417716-92-8
39
Durvalumab Approved, Investigational Phase 2 1428935-60-7
40
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
41
Pembrolizumab Approved Phase 2 1374853-91-4
42
Trametinib Approved Phase 2 871700-17-3 11707110
43
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
44
Ipilimumab Approved Phase 2 477202-00-9
45
nivolumab Approved Phase 2 946414-94-4
46
Tyrosine Approved, Investigational, Nutraceutical Phase 2,Phase 1 60-18-4 6057
47
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
48
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
49
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
50
Alfacalcidol Approved, Nutraceutical Phase 2 41294-56-8 5282181

Interventional clinical trials:

(show top 50) (show all 122)
# Name Status NCT ID Phase Drugs
1 Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer Completed NCT01083550 Phase 2, Phase 3
2 Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC Completed NCT01137097 Phase 2, Phase 3
3 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Completed NCT00795782 Phase 3
4 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
5 Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Recruiting NCT01149161 Phase 2, Phase 3
6 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
7 A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
8 High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer Active, not recruiting NCT00415233 Phase 3
9 ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer Not yet recruiting NCT03570021 Phase 3
10 Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer Unknown status NCT00098852 Phase 2 rosiglitazone maleate
11 Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer Unknown status NCT01118065 Phase 2 everolimus
12 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
13 Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer Completed NCT02408887 Phase 2
14 Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Completed NCT00559949 Phase 2 Selumetinib
15 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Completed NCT00085293 Phase 2 Decitabine
16 A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation Completed NCT01286753 Phase 2 Vemurafenib
17 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
18 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
19 Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection Completed NCT00630214 Phase 2
20 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
21 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2 Fostamatinib disodium
22 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers Completed NCT01524978 Phase 2 cetuximab;vemurafenib;vemurafenib
23 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine Completed NCT00098813 Phase 2 romidepsin
24 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed NCT00118248 Phase 2 tanespimycin
25 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
26 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
27 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed NCT00519896 Phase 2 sunitinib malate
28 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Completed NCT00134043 Phase 2 vorinostat
29 Thalidomide in Treating Patients With Thyroid Cancer Completed NCT00026533 Phase 2 thalidomide
30 Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer Completed NCT00061906 Phase 2 celecoxib
31 Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
32 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Completed NCT00095836 Phase 2 Gefitinib
33 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
34 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
35 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
36 Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer Recruiting NCT02138214 Phase 2
37 Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Recruiting NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
38 Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
39 Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial Recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
40 A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors Recruiting NCT03899792 Phase 1, Phase 2 LOXO-292
41 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Recruiting NCT02568267 Phase 2 Entrectinib
42 Lenvatinib and Pembrolizumab in DTC Recruiting NCT02973997 Phase 2 Lenvatinib
43 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02393690 Phase 2 Selumetinib
44 Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02152995 Phase 2 Trametinib
45 Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer Recruiting NCT03157128 Phase 1, Phase 2 LOXO-292
46 Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
47 Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib Maleate;Lenalidomide
48 Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
49 Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer Active, not recruiting NCT01709292 Phase 2 Vemurafenib (All Groups);Vemurafenib (Post Surgery) - Group A + C
50 Cabozantinib, Nivolumab, and Ipilimumab in Treating Patients With Radioactive Iodine-Refractory Differentiated Thyroid Cancer That Progressed After VEGFR-Targeted Therapy Not yet recruiting NCT03914300 Phase 2 Cabozantinib;Cabozantinib S-malate

Search NIH Clinical Center for Thyroid Cancer, Nonmedullary, 1

Genetic Tests for Thyroid Cancer, Nonmedullary, 1

Genetic tests related to Thyroid Cancer, Nonmedullary, 1:

# Genetic test Affiliating Genes
1 Papillary Thyroid Carcinoma 30

Anatomical Context for Thyroid Cancer, Nonmedullary, 1

MalaCards organs/tissues related to Thyroid Cancer, Nonmedullary, 1:

42
Thyroid, Lymph Node, Endothelial, Myeloid, Pituitary, Brain, B Cells

Publications for Thyroid Cancer, Nonmedullary, 1

Articles related to Thyroid Cancer, Nonmedullary, 1:

(show top 50) (show all 3291)
# Title Authors Year
1
Aggressive papillary thyroid carcinoma in a child with type 2 congenital generalized lipodystrophy. ( 30864635 )
2019
2
Ectopic Papillary Thyroid Carcinoma Mimicking Esophageal Cancer in FDG PET: A Case Report. ( 30394932 )
2019
3
Papillary thyroid carcinoma in cervical lymph nodes with vanished thyroid gland after ablation of Graves' disease by radioactive iodine. ( 30854863 )
2019
4
BRAF gene mutations in synchronous papillary thyroid carcinoma and Langerhans cell histiocytosis co-existing in the thyroid gland: a case report and literature review. ( 30795755 )
2019
5
Oncocytic and tall columnar type papillary thyroid carcinoma arising on a mature cystic teratoma: A case report and literature review. ( 30623925 )
2019
6
Synchronous primary hyperparathyroidism, follicular thyroid carcinoma, and papillary thyroid carcinoma. ( 30614854 )
2019
7
Lipase member H is a downstream molecular target of hypoxia inducible factor-1α and promotes papillary thyroid carcinoma cell migration in BCPAP and KTC-1 cell lines. ( 30774423 )
2019
8
Simultaneous Hodgkin lymphoma and BRAFV600E-positive papillary thyroid carcinoma: A case report. ( 30653166 )
2019
9
Composite poorly differentiated mucoepidermoid carcinoma of the thyroid and follicular variant of papillary thyroid carcinoma. Report of a case and review of the literature. ( 30967930 )
2019
10
Sonographic Characteristics of Papillary Thyroid Carcinoma with Coexistent Hashimoto's Thyroiditis: Conventional Ultrasound, Acoustic Radiation Force Impulse Imaging and Contrast-Enhanced Ultrasound. ( 30528690 )
2019
11
Solid papillary thyroid carcinoma with Hashimoto's thyroiditis: description of a further case with challenging cytological features. ( 30659000 )
2019
12
Thyroid Antibody Status is Associated with Central Lymph Node Metastases in Papillary Thyroid Carcinoma Patients with Hashimoto's Thyroiditis. ( 30937662 )
2019
13
Oncogenic Ras/squamous cell carcinoma antigen signaling pathway activation promotes invasiveness and lymph node metastases in papillary thyroid carcinoma. ( 30535496 )
2019
14
Post-surgical Thyroid Bed Pyoderma Gangrenosum Mimicking Recurrent Papillary Thyroid Carcinoma. ( 31057489 )
2019
15
Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma in the Same Patient as a Collision Tumour. ( 30993022 )
2019
16
High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study. ( 30694737 )
2019
17
Expression of activator protein-1 in papillary thyroid carcinoma and its clinical significance. ( 30704487 )
2019
18
microRNA-539 functions as a tumor suppressor in papillary thyroid carcinoma via the transforming growth factor β1/Smads signaling pathway by targeting secretory leukocyte protease inhibitor. ( 30706537 )
2019
19
Nomogram for predicting level V lymph node metastases in papillary thyroid carcinoma with clinically lateral lymph node metastases: A large retrospective cohort study of 1037 patients from FDUSCC. ( 30719177 )
2019
20
MYC promotes the development of papillary thyroid carcinoma by inhibiting the expression of lncRNA PAX8‑AS1:28. ( 30720110 )
2019
21
Comparison of Mean Platelet Volume, Platelet Count, Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in the Euthyroid, Overt Hypothyroid and Subclinical Hyperthyroid Phases of Papillary Thyroid Carcinoma. ( 30727930 )
2019
22
Evaluation of prognostic usefulness of long noncoding RNA GAS5 and FAL1 in papillary thyroid carcinoma. ( 30746742 )
2019
23
Letter to the Editor regarding, "Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: A single-institution matched-pair analysis". ( 30773348 )
2019
24
Feasibility and safety of needle-assisted endoscopic thyroidectomy with lateral neck dissection for papillary thyroid carcinoma: a preliminary experience. ( 30775820 )
2019
25
MiR-202-3p functions as a tumor suppressor and reduces cell migration and invasion in papillary thyroid carcinoma. ( 30779083 )
2019
26
Concurrent Papillary Thyroid Carcinoma and Synovial Carcinoma of the Neck in an Adult Male. ( 30783603 )
2019
27
Relationship between genetic alterations and clinicopathological characteristics of papillary thyroid carcinoma. ( 30788603 )
2019
28
FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway. ( 30793770 )
2019
29
Circular RNA circBACH2 plays a role in papillary thyroid carcinoma by sponging miR-139-5p and regulating LMO4 expression. ( 30796202 )
2019
30
DNA methylation-mediated silencing of miR-204 is a potential prognostic marker for papillary thyroid carcinoma. ( 30799952 )
2019
31
Repeat Ultrasonography in the First Years after Therapy with Radioiodine Is Not Necessary in Most Patients with Papillary Thyroid Carcinoma when Postoperative Ultrasonography Is Negative: A Reduction of Costs and False-Positives. ( 30800640 )
2019
32
Leukocyte telomere length and risk of papillary thyroid carcinoma. ( 30817819 )
2019
33
Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR. ( 30819583 )
2019
34
Individual prediction of lateral neck metastasis risk in patients with unifocal papillary thyroid carcinoma. ( 30824213 )
2019
35
Targeted next-generation sequencing in papillary thyroid carcinoma patients looking for germline variants predisposing to the disease. ( 30826992 )
2019
36
MicroRNA-101 targets CXCL12-mediated Akt and Snail signaling pathways to inhibit cellular proliferation and invasion in papillary thyroid carcinoma. ( 30832753 )
2019
37
Influence of Body Mass Index on the Clinicopathologic Features of Papillary Thyroid Carcinoma. ( 30841713 )
2019
38
Cutaneous Metastasis of a Papillary Thyroid Carcinoma. ( 30841736 )
2019
39
Previously undescribed thyroid-specific miRNA sequences in papillary thyroid carcinoma. ( 30842597 )
2019
40
Preoperative serum VEGF-C but not VEGF-A level is correlated with lateral neck metastasis in papillary thyroid carcinoma. ( 30843635 )
2019
41
Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: A single-institution matched-pair analysis. ( 30846171 )
2019
42
Use of Delphian lymph node metastasis to predict central and lateral involvement in papillary thyroid carcinoma: A systematic review and meta-analysis. ( 30851206 )
2019
43
Papillary thyroid carcinoma with bilateral axillary lymph node involvement: a case report outlining hypothesis for locoregional spread and therapeutic implications. ( 30854508 )
2019
44
Correlations of lncRNAs with cervical lymph node metastasis and prognosis of papillary thyroid carcinoma. ( 30863094 )
2019
45
Tumor Volume Doubling Time in Active Surveillance of Papillary Thyroid Carcinoma. ( 30864894 )
2019
46
Important cytological findings for distinction between follicular variant and conventional papillary thyroid carcinoma, including noninvasive follicular thyroid tumors with papillary-like nuclear features. ( 30867345 )
2019
47
TGF-β1 promotes the invasion and migration of papillary thyroid carcinoma cells by inhibiting the expression of lncRNA-NEF. ( 30867742 )
2019
48
Exosomal miRNA423-5p mediated oncogene activity in papillary thyroid carcinoma: a potential diagnostic and biological target for cancer therapy. ( 30868891 )
2019
49
Identification and analysis of genes associated with papillary thyroid carcinoma by bioinformatics methods. ( 30872410 )
2019
50
Association Between Radiomics Signature and Disease-Free Survival in Conventional Papillary Thyroid Carcinoma. ( 30872763 )
2019

Variations for Thyroid Cancer, Nonmedullary, 1

UniProtKB/Swiss-Prot genetic disease variations for Thyroid Cancer, Nonmedullary, 1:

76
# Symbol AA change Variation ID SNP ID
1 NKX2-1 p.Ala339Val VAR_075769 rs537209983

ClinVar genetic disease variations for Thyroid Cancer, Nonmedullary, 1:

6 (show all 17)
# Gene Variation Type Significance SNP ID Assembly Location
1 BRAF NM_004333.5(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
2 BRAF NM_004333.5(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
3 BRAF NM_004333.5(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605
4 MSH2 NM_000251.2(MSH2): c.1706A> G (p.Glu569Gly) single nucleotide variant Uncertain significance rs786201077 GRCh37 Chromosome 2, 47698148: 47698148
5 MSH2 NM_000251.2(MSH2): c.1706A> G (p.Glu569Gly) single nucleotide variant Uncertain significance rs786201077 GRCh38 Chromosome 2, 47471009: 47471009
6 NKX2-1 NM_001079668.2(NKX2-1): c.1106C> T (p.Ala369Val) single nucleotide variant Likely benign rs537209983 GRCh37 Chromosome 14, 36986583: 36986583
7 NKX2-1 NM_001079668.2(NKX2-1): c.1106C> T (p.Ala369Val) single nucleotide variant Likely benign rs537209983 GRCh38 Chromosome 14, 36517378: 36517378
8 PCM1 NM_006197.3(PCM1): c.2935C> T (p.Gln979Ter) single nucleotide variant Uncertain significance rs1085307084 GRCh37 Chromosome 8, 17823587: 17823587
9 PCM1 NM_006197.3(PCM1): c.2935C> T (p.Gln979Ter) single nucleotide variant Uncertain significance rs1085307084 GRCh38 Chromosome 8, 17966078: 17966078
10 PALB2 NM_024675.3(PALB2): c.2147A> G (p.Asn716Ser) single nucleotide variant Uncertain significance rs148335539 GRCh37 Chromosome 16, 23641328: 23641328
11 PALB2 NM_024675.3(PALB2): c.2147A> G (p.Asn716Ser) single nucleotide variant Uncertain significance rs148335539 GRCh38 Chromosome 16, 23630007: 23630007
12 RUNX1 NM_001754.4(RUNX1): c.749G> A (p.Arg250His) single nucleotide variant Uncertain significance rs771614642 GRCh38 Chromosome 21, 34834466: 34834466
13 RUNX1 NM_001754.4(RUNX1): c.749G> A (p.Arg250His) single nucleotide variant Uncertain significance rs771614642 GRCh37 Chromosome 21, 36206763: 36206763
14 LIG4 NM_002312.3(LIG4): c.1673A> C (p.Gln558Pro) single nucleotide variant Likely pathogenic GRCh38 Chromosome 13, 108209596: 108209596
15 LIG4 NM_002312.3(LIG4): c.1673A> C (p.Gln558Pro) single nucleotide variant Likely pathogenic GRCh37 Chromosome 13, 108861944: 108861944
16 CDH1 NM_004360.5(CDH1): c.2351G> C (p.Arg784Pro) single nucleotide variant Uncertain significance GRCh38 Chromosome 16, 68829709: 68829709
17 CDH1 NM_004360.5(CDH1): c.2351G> C (p.Arg784Pro) single nucleotide variant Uncertain significance GRCh37 Chromosome 16, 68863612: 68863612

Cosmic variations for Thyroid Cancer, Nonmedullary, 1:

9 (show top 50) (show all 1180)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6961574 ZFHX3 thyroid,NS,carcinoma,papillary carcinoma c.5539C>T p.Q1847* 16:72797143-72797143 0
2 COSM7339522 ZBTB2 thyroid,NS,carcinoma,papillary carcinoma c.1012C>G p.P338A 6:151366054-151366054 0
3 COSM7339681 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.1801C>G p.Q601E 2:61492121-61492121 0
4 COSM7340098 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.994G>T p.E332* 2:61495508-61495508 0
5 COSM7339812 WT1 thyroid,NS,carcinoma,papillary carcinoma c.494C>G p.S165W 11:32428568-32428568 0
6 COSM6954354 VTCN1 thyroid,NS,carcinoma,papillary carcinoma c.399C>G p.I133M 1:117156620-117156620 0
7 COSM17721 VHL thyroid,NS,carcinoma,papillary carcinoma c.241C>T p.P81S 3:10142088-10142088 0
8 COSM26416 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1867G>T p.A623S 14:81143925-81143925 0
9 COSM26497 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1915C>T p.P639S 14:81143973-81143973 0
10 COSM26449 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1358T>C p.M453T 14:81143416-81143416 0
11 COSM26417 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1868C>T p.A623V 14:81143926-81143926 0
12 COSM26419 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1897G>T p.D633Y 14:81143955-81143955 0
13 COSM7340068 TSHR thyroid,NS,carcinoma,papillary carcinoma c.572C>T p.S191L 14:81096665-81096665 0
14 COSM7339928 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4760G>A p.C1587Y 16:2086290-2086290 0
15 COSM6918838 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4468G>C p.E1490Q 16:2084690-2084690 0
16 COSM7340474 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4433A>T p.D1478V 16:2084655-2084655 0
17 COSM7340359 TRRAP thyroid,NS,carcinoma,papillary carcinoma c.7672A>C p.T2558P 7:98971853-98971853 0
18 COSM7340196 TP53BP1 thyroid,NS,carcinoma,papillary carcinoma c.910G>T p.E304* 15:43477623-43477623 0
19 COSM7340198 TP53BP1 thyroid,NS,carcinoma,papillary carcinoma c.5465G>T p.G1822V 15:43409017-43409017 0
20 COSM10771 TP53 thyroid,NS,carcinoma,papillary carcinoma c.749C>T p.P250L 17:7674214-7674214 0
21 COSM10654 TP53 thyroid,NS,carcinoma,papillary carcinoma c.637C>T p.R213* 17:7674894-7674894 0
22 COSM10659 TP53 thyroid,NS,carcinoma,papillary carcinoma c.817C>T p.R273C 17:7673803-7673803 0
23 COSM10867 TP53 thyroid,NS,carcinoma,papillary carcinoma c.797G>A p.G266E 17:7673823-7673823 0
24 COSM10646 TP53 thyroid,NS,carcinoma,papillary carcinoma c.725G>A p.C242Y 17:7674238-7674238 0
25 COSM10726 TP53 thyroid,NS,carcinoma,papillary carcinoma c.856G>A p.E286K 17:7673764-7673764 0
26 COSM11196 TP53 thyroid,NS,carcinoma,papillary carcinoma c.734G>T p.G245V 17:7674229-7674229 0
27 COSM43951 TP53 thyroid,NS,carcinoma,papillary carcinoma c.643A>G p.S215G 17:7674888-7674888 0
28 COSM10648 TP53 thyroid,NS,carcinoma,papillary carcinoma c.524G>A p.R175H 17:7675088-7675088 0
29 COSM43723 TP53 thyroid,NS,carcinoma,papillary carcinoma c.398T>C p.M133T 17:7675214-7675214 0
30 COSM10662 TP53 thyroid,NS,carcinoma,papillary carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
31 COSM10758 TP53 thyroid,NS,carcinoma,papillary carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
32 COSM5444226 TP53 thyroid,NS,carcinoma,papillary carcinoma c.96+1G>C p.? 17:7676381-7676381 0
33 COSM44225 TP53 thyroid,NS,carcinoma,papillary carcinoma c.859G>A p.E287K 17:7673761-7673761 0
34 COSM10739 TP53 thyroid,NS,carcinoma,papillary carcinoma c.481G>A p.A161T 17:7675131-7675131 0
35 COSM44922 TP53 thyroid,NS,carcinoma,papillary carcinoma c.670G>T p.E224* 17:7674861-7674861 0
36 COSM44338 TP53 thyroid,NS,carcinoma,papillary carcinoma c.845G>A p.R282Q 17:7673775-7673775 0
37 COSM10812 TP53 thyroid,NS,carcinoma,papillary carcinoma c.722C>T p.S241F 17:7674241-7674241 0
38 COSM44101 TP53 thyroid,NS,carcinoma,papillary carcinoma c.417G>C p.K139N 17:7675195-7675195 0
39 COSM10660 TP53 thyroid,NS,carcinoma,papillary carcinoma c.818G>A p.R273H 17:7673802-7673802 0
40 COSM10667 TP53 thyroid,NS,carcinoma,papillary carcinoma c.646G>A p.V216M 17:7674885-7674885 0
41 COSM11183 TP53 thyroid,NS,carcinoma,papillary carcinoma c.799C>T p.R267W 17:7673821-7673821 0
42 COSM43801 TP53 thyroid,NS,carcinoma,papillary carcinoma c.716A>C p.N239T 17:7674247-7674247 0
43 COSM43980 TP53 thyroid,NS,carcinoma,papillary carcinoma c.691A>G p.T231A 17:7674272-7674272 0
44 COSM10863 TP53 thyroid,NS,carcinoma,papillary carcinoma c.833C>T p.P278L 17:7673787-7673787 0
45 COSM11114 TP53 thyroid,NS,carcinoma,papillary carcinoma c.528C>G p.C176W 17:7675084-7675084 0
46 COSM44988 TP53 thyroid,NS,carcinoma,papillary carcinoma c.374C>T p.T125M 17:7675995-7675995 0
47 COSM10705 TP53 thyroid,NS,carcinoma,papillary carcinoma c.586C>T p.R196* 17:7674945-7674945 0
48 COSM10731 TP53 thyroid,NS,carcinoma,papillary carcinoma c.707A>G p.Y236C 17:7674256-7674256 0
49 COSM10735 TP53 thyroid,NS,carcinoma,papillary carcinoma c.638G>A p.R213Q 17:7674893-7674893 0
50 COSM10738 TP53 thyroid,NS,carcinoma,papillary carcinoma c.542G>A p.R181H 17:7675070-7675070 0

Copy number variations for Thyroid Cancer, Nonmedullary, 1 from CNVD:

7 (show all 16)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13343 1 1 124300000 Chromosomal rearrang ement Papillary thyroid carcinoma
2 13804 1 1 60900000 Chromosomal rearrang ement Papillary thyroid carcinoma
3 19995 1 152394403 152431233 Translate TPM3 Papillary thyroid carcinoma
4 42899 10 42100000 53300000 Chromosomal rearrang ement Papillary thyroid carcinoma
5 44673 10 61218526 61336824 Translate D10S170 Papillary thyroid carcinoma
6 91970 15 37900000 47600000 Copy number FGF7 Papillary thyroid carcinoma
7 95418 15 76100000 86900000 Copy number AKAP13 Papillary thyroid carcinoma
8 96732 15 92330402 92376057 Translate GOLGA5 Papillary thyroid carcinoma
9 106730 17 1 11200000 Copy number TRE2 Papillary thyroid carcinoma
10 140387 2 197100000 209100000 Copy number TRAK2 Papillary thyroid carcinoma
11 148729 2 83700000 91000000 Amplification TB10 Papillary thyroid carcinoma
12 166063 3 1 14700000 Chromosomal rearrang ement Papillary thyroid carcinoma
13 166395 3 101910849 101950501 Translate TFG Papillary thyroid carcinoma
14 194280 5 139000000 143100000 Copy number EIF4EBP3 Papillary thyroid carcinoma
15 219438 7 126900000 158821424 Chromosomal rearrangement Papillary thyroid carcinoma
16 232143 8 112100000 146364022 Amplification Papillary thyroid cancer

Expression for Thyroid Cancer, Nonmedullary, 1

Search GEO for disease gene expression data for Thyroid Cancer, Nonmedullary, 1.

Pathways for Thyroid Cancer, Nonmedullary, 1

Pathways related to Thyroid Cancer, Nonmedullary, 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.51 MIR221 MIR222
2 9.7 HOTAIR LINC-ROR

GO Terms for Thyroid Cancer, Nonmedullary, 1

Biological processes related to Thyroid Cancer, Nonmedullary, 1 according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of epithelial cell migration GO:0010634 9.51 MIR221 MIR222
2 positive regulation of erythrocyte differentiation GO:0045648 9.49 MIR221 MIR222
3 thyroid gland development GO:0030878 9.48 BRAF NKX2-1
4 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.46 MIR221 MIR222
5 negative regulation by host of viral genome replication GO:0044828 9.43 MIR221 MIR222
6 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.4 MIR221 MIR222
7 negative regulation of cell adhesion molecule production GO:0060354 9.37 MIR221 MIR222
8 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.32 MIR221 MIR222
9 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.26 MIR221 MIR222
10 positive regulation of Schwann cell migration GO:1900149 9.16 MIR221 MIR222
11 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 8.96 MIR221 MIR222
12 positive regulation of axon regeneration GO:0048680 8.8 BRAF MIR221 MIR222

Sources for Thyroid Cancer, Nonmedullary, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....